EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Andreu Vilaseca, Philippe A Bilodeau, Georgios Gakis, Andrea Savransky, Joao Mahler Ferreira Oliveira, Linda Nguyen, Sam I Hooshmand, Sammita Satyanarayan, Carson E Moseley, Leah Haley, Chantal Roy-Hewitson, Mariano Marrodan und 46 weitere

JAMA Neurology · 01.09.2026 · 83 (9) · 860

DOI: 10.1001/jamaneurol.2026.2220 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Neurology, erschienen am 01.09.2026. Verfasst von Andreu Vilaseca und 57 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota. Hauptthemen laut MEDLINE: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Receptors, Interleukin-6, Antibodies, Monoclonal, Humanized, Secondary Prevention. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) lacks proven relapse-preventive therapies. While clinical trials are ongoing, safety data may be limited and approved drugs are costly. Studies of interleukin 6 receptor blocker (IL-6RB) in MOGAD are limited by small numbers and no comparative studies, contributing to low use.

Objective

To evaluate the impact of IL-6RB therapy on relapse rates in MOGAD and compare relapse frequency with intravenous immunoglobulin (IVIG). Design, Setting, and Participants This international, multicenter, retrospective cohort study (January 1, 2015, through December 31, 2025) included a historical IVIG-treated cohort of varying doses. The study took place across sites in North and South America (US, Canada, Mexico, Argentina, Brazil, Chile, Colombia, and Peru). Patients with MOGAD (n = 116, no excluded patients) who received at least 1 dose of an IL-6RB were included. These data were analyzed in January 2026. Exposures Tocilizumab or satralizumab. Main Outcomes and Measures Annualized relapse rate (ARR) during IL-6RB therapy, time to next relapse after treatment initiation, and adverse events. Outcomes were compared with the IVIG cohort using inverse probability of treatment weighting (IPTW) adjusted for age, sex, prior ARR, and concomitant therapies.

Results

A total of 116 patients with MOGAD (89% relapsing) receiving IL-6RB (tocilizumab, 104 [90%] and satralizumab, 12 [10%]) were included; overall, 60.3% were female, 39.7% were male, and 18% were younger than 18 years. The median (IQR) IL-6RB treatment follow-up was 1.4 (0.7-2.5) years and 23 relapses occurred during 241.8 person-years of IL-6RB therapy. The ARR decreased from 0.64 (95% CI, 0.58-0.70) for relapsing MOGAD before IL-6RB to 0.09 (95% CI, 0.06-0.14) during IL-6RB treatment (incidence rate ratio, 0.08; 95% CI, 0.04-0.16). Adverse events occurred in 58 patients (50%), most commonly mild infections, although 10 (9%) had severe infections. In the IVIG cohort (n = 59), 30 relapses occurred over 133.8 person-years (ARR, 0.22; 95% CI, 0.15-0.32). After IPTW, IL-6RB was associated with a lower hazard ratio (HR) than the group who underwent IVIG therapy less than 1 g/kg every 4 weeks (HR, 4.5; 95% CI, 2.0-9.8), with no significant difference vs the group who underwent IVIG 1 g/kg or more every 4 weeks (HR, 2.0; 95% CI, 0.8-4.5). Conclusions and Relevance In this multicenter observational cohort, IL-6RB use in MOGAD was associated with low relapse rates and a favorable safety profile, though severe infections occurred occasionally. Relapse rates were lower than the group who underwent IVIG less than 1 g/kg every 4 weeks but not significantly different from the group who underwent IVIG 1 g/kg or more every 4 weeks. This supports IL-6RB as a potential relapse-prevention therapy in MOGAD; the wide availability and relative affordability of tocilizumab may enable broad global use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseReceptors, Interleukin-6Antibodies, Monoclonal, HumanizedSecondary PreventionHumansFemaleMaleRetrospective StudiesAdultImmunoglobulins, IntravenousRecurrenceCohort StudiesYoung AdultMyelin-Oligodendrocyte Glycoprotein

Substanzen

Receptors, Interleukin-6Antibodies, Monoclonal, HumanizedtocilizumabImmunoglobulins, IntravenousMyelin-Oligodendrocyte Glycoprotein

Autor:innen und Institutionen

  • Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
  • Massachusetts General Hospital and Harvard Medical School, Boston.
  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Paediatric Neuroimmunology Clinic, Department of Neurology, National Paediatric Hospital Dr J P Garrahan, Ciudad de Buenos Aires, Argentina.
  • Department of Neurology, University of Texas Southwestern Medical Center, Dallas.
  • Department of Neurology, Medical College of Wisconsin, Milwaukee.

Förderung

  • NINDS NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Vilaseca, A., Bilodeau, P. A., Gakis, G., Savransky, A., Mahler Ferreira Oliveira, J., Nguyen, L., Hooshmand, S. I., Satyanarayan, S., Moseley, C. E., Haley, L., Roy-Hewitson, C., Marrodan, M., Casallas, A., Manin, A., Chen, H., Hoshina, Y., Grzezulkowska, A., Carnero Contentti, E., Galleguillos, L., …, & Horsman, S. E. (2026). Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. JAMA Neurology, 83(9), 860. https://doi.org/10.1001/jamaneurol.2026.2220

Vancouver

Vilaseca A, Bilodeau PA, Gakis G, Savransky A, Mahler Ferreira Oliveira J, Nguyen L, et al. Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. JAMA Neurology. 2026;83(9):860. doi:10.1001/jamaneurol.2026.2220

BibTeX
@article{Vilaseca2026,
  author = {Vilaseca, Andreu and Bilodeau, Philippe A and Gakis, Georgios and Savransky, Andrea and Mahler Ferreira Oliveira, Joao and Nguyen, Linda and Hooshmand, Sam I and Satyanarayan, Sammita and Moseley, Carson E and Haley, Leah and Roy-Hewitson, Chantal and Marrodan, Mariano and Casallas, Adriana and Manin, Analisa and Chen, Haiwen and Hoshina, Yoji and Grzezulkowska, Aniela and Carnero Contentti, Edgar and Galleguillos, Lorna and Upchurch, Margaret and Jackson-Tarlton, Caitlin S and Chu-Yueh Guo, Joanne and Fabian, Michelle and Virupakshaiah, Akash and Arrambide, Georgina and Caparó-Zamalloa, César and Paterno, Rafael and Waubant, Emmanuelle and Ordoñez Boschetti, Laura and Correale, Jorge and Villa, Andres M and Banwell, Brenda and Marignier, Romain and Pittock, Sean J and Greenberg, Benjamin and Bennett, Jeffrey L and Cho, Tracey and Clardy, Stacey and Solomon, Andrew J and Kister, Ilya and Zamvil, Scott S and Gelfand, Jeffrey M and Repovic, Pavle and Obeidat, Ahmed Z and Blackburn, Kyle and Tenembaum, Silvia and Chen, John J and Sotirchos, Elias S and Levy, Michael and Flanagan, Eoin P and and The Americas MOGAD Treatment Group, and The Americas MOGAD Treatment Group and Murillo, Fabian and Syc-Mazurzek, Stephanie B and Cacciaguerra, Laura and Jiang, Mulan and da Silva Rezende, Nathane Braga and Wingerchuk, Dean M and Horsman, Susan E},
  title = {Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease},
  journal = {JAMA Neurology},
  year = {2026},
  volume = {83},
  number = {9},
  pages = {860},
  doi = {10.1001/jamaneurol.2026.2220}
}
Kostenlos starten →